Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
¿ø¹ß¼º °íÇ÷¾Ð¿¡ ´ëÇÑ ¾ËÆÄÂ÷´ÜÁ¦ÀÇ Ç÷¾Ð °­ÇÏ È¿°ú

Blood pressure lowering efficacy of alpha blockers for primary hypertension
Balraj S Heran, Brandon P Galm, James M Wright
15 August 2012
°ËÅä±×·ì : °íÇ÷¾Ð±×·ì(Hypertension Group)
ÄÚÅ©¶õ¸µÅ© :

¿¬±¸ ¹è°æ

¾ËÆÄÂ÷´ÜÁ¦´Â ¶§¶§·Î °íÇ÷¾Ð¿¡ ó¹æµÇ±â ¶§¹®¿¡ Ç÷¾Ð, ½É¹Ú¼ö ¹× ºÎÀÛ¿ëÀ¸·Î ÀÎÇÑ ±Ý´Ü(WDAE)¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» °áÁ¤ÇÏ°í ºñ±³ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.

¿¬±¸ ¸ñÀû

¿ø¹ß¼º °íÇ÷¾ÐÀÇ Ä¡·á¿¡ ÀÖ¾î À§¾à¿¡ ºñÇØ ¾ËÆÄÂ÷´ÜÁ¦ÀÇ Åõ¿©·®-°ü·Ã ¼öÃà±â ¶Ç´Â È®Àå±â Ç÷¾Ð °­ÇÏ È¿°ú¸¦ Á¤·®Çϱâ À§ÇÔ.

Á¶»ç ¹æ¹ý

¾÷µ¥ÀÌÆ®µÈ °íÂû¿¡¼­ ¿ì¸®´Â CENTRAL(The Cochrane Library 2012, Issue 4), MEDLINE (1946³â~ 2012³â 5¿ù), EMBASE (1980³â 5¿ù~2012³â 5¿ù) ¹× ³í¹®ÀÇ Âü°í¹®ÇåÀ» °Ë»öÇß´Ù.

¼±Åà ±âÁØ

¿ø¹ß¼º °íÇ÷¾Ð ȯÀÚ¿¡¼­ 3-12ÁÖ°£ À§¾à¿¡ ºñÇØ ¾ËÆÄÂ÷´ÜÁ¦¸¦ »ç¿ëÇÏ¿© °íÁ¤¿ë·® ´ÜÀÏ¿ä¹ýÀÇ Ç÷¾Ð °­ÇÏ È¿°ú¸¦ Æò°¡ÇÏ´Â ÀÌÁß ¸Í°Ë, ¹«ÀÛÀ§´ëÁ¶½ÃÇè.

µ¥ÀÌÅÍ ¼öÁý°ú ºÐ¼®

2¸íÀÇ ÀúÀÚ°¡ µ¶¸³ÀûÀ¸·Î ¹ÙÀ̾ÀÇ À§ÇèÀ» Æò°¡ÇÏ°í ÀڷḦ ÃßÃâÇß´Ù. Ãß°¡ Á¤º¸´Â ¿¬±¸ ÀúÀÚ¿¡°Ô ¹®ÀÇÇß´Ù. WDAE Á¤º¸´Â ÀÓ»ó½ÃÇè¿¡¼­ ¼öÁýµÇ¾ú´Ù.

ÁÖ¿ä °á°ú

10°ÇÀÇ ÀÓ»ó½ÃÇ踸ÀÌ Åõ¿©·®-°ü·Ã ÃÖÀúÇ÷¾ÐÀ» Æò°¡ÇÏ¿© 1175¸íÀÇ Âü°¡ÀÚ¿¡¼­ 4°ÇÀÇ ´Ù¸¥ ¾ËÆÄÂ÷´ÜÁ¦ÀÇ È¿´ÉÀ» ÀúÇϽÃÄ×À¸¸ç, ±âÁØ Ç÷¾ÐÀº 155/101mm Hg¿´´Ù. ÀÌ ÀÚ·á´Â ¾î´À ÇÑ ¾ËÆÄÂ÷´ÜÁ¦°¡ Ç÷¾ÐÀ» ³·Ãߴµ¥ ´õ ÁÁ°Å³ª ³ª»Ú´Ù°í Á¦¾ÈÇÏÁö ¾Ê´Â´Ù. ¾ËÆÄÂ÷´ÜÁ¦¿¡ ´ëÇÑ È¿°ú¸¦ ³·Ãß´Â ÃÖÀúÇ÷¾ÐÀÇ °¡Àå ÁÁÁö¸¸ ºÒ¸¸Á·½º·¯¿î ÃßÁ¤Ä¡´Â -8/-5 mmHgÀÌ´Ù.

ÀúÀÚµéÀÇ °á·Ð

¹ßÇ¥µÈ RCTÀÇ Á¦ÇÑµÈ ¼ö¿¡ ±â¹ÝÇÏ¿©, ¾ËÆÄÂ÷´ÜÁ¦ÀÇ Ç÷¾Ð °­ÇÏ È¿°ú´Â ¿Ï¸¸ÇÏ´Ù. ÃÖÀúÇ÷¾ÐÀÌ -8/-5 mmHg ³·¾ÆÁö´Â Á¤µµ¸¦ ¿¹ÃøÇÏ´Â °ÍÀÌ °ú´ëÆò°¡µÉ °¡´É¼ºÀÌ ÀÖ´Ù. ´Ù¸¥ ¾ËÆÄÂ÷´ÜÁ¦ °£¿¡´Â ÀÓ»óÀûÀ¸·Î ÀǹÌÀÖ´Â Ç÷¾Ð °­ÇÏ Â÷ÀÌ°¡ ¾ø´Ù. °íÂû¿¡¼­´Â ÀÓ»ó½ÃÇè ±â°£ÀÌ Âª°í ¸¹Àº ÀÓ»ó½ÃÇè¿¡¼­ ºÎÀÛ¿ë º¸°í°¡ ¾ø±â ¶§¹®¿¡ ¾ËÆÄÂ÷´ÜÁ¦¿Í °ü·ÃµÈ À¯ÇØ »ç·Ê¿¡ ´ëÇÑ ÁÁÀº ¿¹ÃøÀ» Á¦°øÇÏÁö ¸øÇß´Ù.

±³½ÅÀúÀÚ
Balraj S Heran
bsheran@ti.ubc.ca. bsheran@gmail.com.
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, British Columbia, V6T 1Z3, Canada.